Peng Sun
Candidate for Council
After receiving his Ph.D. degree in statistics in 2006
from the University of Iowa, Peng worked in clinical
pharmacology statistics group at Merck for four years
before joining GSK. At GSK, Peng was the lead
statistician for the global submission of a combination
treatment for metastatic melanoma that received
accelerated approval from the FDA. Peng joined Biogen
in 2015 and he severed as the lead statistician for the
global submission of Spinraza, the first approved drug
for the treatment of spinal muscular atrophy (SMA).
Peng is currently the statistics head for the
neuromuscular franchise at Biogen.
